Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

NewKI, one of UK’s largest observational studies of incident chronic kidney disease (CKD) in general practice, gets underway this month, involving 3,205 Oxfordshire residents and led by Oxford University researchers.

Over the next two years, the New onset Kidney Impairment (NewKI) study will work with 13 Oxfordshire GP surgeries to investigate how people over the age of 60 progress from mild to more severe forms of CKD. This could help doctors to better identify and treat those at risk.

Kidney function declines slowly with age, and around 1 in 10 people have mild chronic kidney disease. Recognised as an international health issue by the World Health Organisation and responsible for 850,000 deaths globally, CKD is associated with an increased risk of developing cardiovascular diseases such as stroke, heart failure and sudden death.

However, very little is known about how many people in the UK have CKD, or the factors that increase someone’s risk of developing the condition and progressing onto more severe forms of kidney decline.

Find out more (Nuffield Department of Primary Care Health Sciences website)

Similar stories

Labelling proteins through the diet gives new insights into how collagen-rich tissues change as we age

A new study, published in eLife, uses advanced tissue analysis technology to show how the incorporation of new proteins changes in bone and cartilage with age.

Drug could help diabetic hearts recover after heart attack - Oxford research

Researchers at the University of Oxford have identified a drug that could ultimately help improve heart function in people with diabetes who have heart attacks.

Largest ever global study of tuberculosis identifies genetic causes of drug resistance

Using cutting-edge genomic sequencing techniques, researchers at the University of Oxford have identified almost all the genomic variation that gives people resistance to 13 of the most common tuberculosis (TB) drug treatments.

Researchers set out steps to address mental health effects of the pandemic on young people

Researchers have outlined 14 steps that schools, mental health services and policymakers can take to help children and young people whose mental health has been affected by the COVID-19 pandemic.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

No benefit of convalescent plasma for critically ill COVID-19 patients

A large study of over 2000 COVID-19 patients has found that giving critically ill patients blood plasma from recovered COVID-19 patients did not significantly reduce deaths, or the need for intensive care support such as being put on a ventilator machine.